Safeco involved in questionable dealings with Polymedica, reports Asensio & Company.

Thomas McGuire manages the SAFECO Growth Opportunities Fund (“Safeco”). Safeco is Polymedica Corporation’s (NASDAQ: PLMD)(Price: $17.40) largest single investor. In July Mr. McGuire was quoted in the New York Times and the Boston Globe saying PLMD was “beaten up because of unsubstantiated rumors and innuendoes.” A month later 85 FBI agents raided eight PLMD offices and warehouses and the homes of two of PLMD’s executives. Safeco still holds its large PLMD position.

Steven Lee is the CEO of PLMD. He is also the co-director of Athena Family Partners, Ltd. Athena and Safeco have participated in private placements for Novavax, Inc (NASDAQ: NVAX)(Price: $14.04) and micro-cap Nastech Pharmaceutical Company, Inc (NASDAQ: NSTK)(Price: $9.50). Novavax is engaged in the promotion of questionable clinical trials and is a spin-off of IGI (AMEX: IG)(Price: $0.88), which committed accounting fraud. Safeco has not disclosed that it invested with PLMD’s CEO in private placements, which could result in a conflict of interest.

Keith Trowbridge is currently the Vice President of PLMD. Before PLMD he was an officer of Transworld Healthcare, Inc. that was found guilty of medicare fraud. Trowbridge was also previously the Chairman and CEO of Medical Associates of America, which obtained funds privately from a mutual fund. The fund manager in charge of the investment was criticized for investing in Medical Associates without disclosing a conflict of interest. In 1994, after it adversely restated its earlier financial disclosures, the company declared bankruptcy.

Today, Asensio & Company, Inc. initiated coverage of PLMD shares with a strong-sell and short-sell recommendation. A report questioning the wisdom of PLMD’s recent stock price recovery is available at

Today PLMD announced results that showed cash declined by $6.8 million despite a $12.6 million increase in payables and that income before taxes dropped sequentially by over 40% despite a $4.3 million increase in unexpensed advertising cost. Total unexpensed advertising cost reached $47 million equal to 80% of PLMD’s entire total cumulative all-time retained earnings. Based purely on fundamentals and irrespective of the likelihood that a federal indictment will result from PLMD’s alleged criminal misconduct, we believe PLMD shares are worth less than $1 per share.

Asensio & Company believes PLMD is grossly overvalued.

Posted in PolyMedica Corporation

Manuel Asensio doesn’t bet often. But when he does, it’s wise to pay attention.

Paul Kaihla
eCompany Now
1 2 3 4 5 6 7 8 9
About Our Founder
Learn more about's founder, Manuel P. Asensio, and the website's origins. Click here to be directed to Mr. Asensio’s professional biography.
Media Record
Click here to see selected articles that discuss's work and its unique legacy. also strives to maintain a complete record of articles dealing with the companies that are the subject of research.
Investment Record
Click here to view a list of the companies that have been subjects of reporting and click here to see the complete investment record.
Asensio and FINRA
Asensio & Company, Inc. and Manuel P. Asensio are the only dedicated short sellers ever to have been members of FINRA. This unique-minority membership created complications in the regulatory relationship. Being the first activist short investors and among the first FINRA member firms with a website added to the complexity. A statement by Mr. Asensio is available here. Information necessary to obtain a meaningful understanding of the dispute is available in complete form HERE.